Agenus Stock Rises Ahead of Investor Day Presentation
Shares of Agenus (NASDAQ: AGEN) rose as much as 12.1% today. While there wasn't any specific news lifting the stock, investors are anticipating good news ahead of the company's investor day, scheduled for tomorrow.
The development-stage biopharmaceutical company is set to present clinical data from two drug candidates at the investor day: a combination therapy comprising AGEN2034 and AGEN1884, and AGEN1181 as a monotherapy. All three experimental therapies are monoclonal antibodies being developed as oncology assets.
As of 3:04 p.m. EST, the pharma stock was trading at its intraday high representing a 12.1% gain.
Source Fool.com
